We examined TMCC2 immunoreactivity in late onset AD cases stratified by APOE genotype and age‐matched non‐demented controls, as well as in early onset AD cases associated with mutations in APP or Down syndrome. This evidence concerns the gene TMCC2 and Down syndrome.